Dr Christian Deleuze, President Genzyme France et Genzyme Polyclonals
For the people who work at Genzyme – a Sanofi Company – our culture of innovation is the product of our own roots and our subsequent development as part of Sanofi Group. It’s the story of a start-up created in 1981 by a group of pioneers dedicated to a mission: to meet the needs of patients waiting for therapeutic solutions for rare diseases - a field as yet unexplored at the time. Our future lies within Sanofi Group, a major player whose “Open Innovation” approach is based on partnerships and expertise sharing.
It was quite logical for us to partner with the ESSEC Chair of Therapeutic Innovation, whose mission is to develop and train talents to meet the innovation challenges of tomorrow: individualized care of patients who will become responsible, connected actors of their health, and integration of the technological, scientific and ethical revolutions, diagnostic tests and targeted therapies, for the greater benefit of all.
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals with world-class research, and through the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Our Partners >